Evoke Pharma, Inc.
12671 High Bluff Drive
Suite 200
San Diego
California
92130
United States
Tel: 858-967-5454
Website: http://www.evokepharma.com/
170 articles about Evoke Pharma, Inc.
-
Evoke Pharma to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
9/9/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief Business Officer, are scheduled to participate virtually in the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – September 16, 2020. Event: H.C. Wainwright 22nd Annua
-
Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti™Gimoti commercial launch on track for the fourth quarter of 2020
8/25/2020
SOLANA BEACH, Calif. and CHICAGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced that EVERSANA has appointed Christopher Quesenberry as Chief Commercial Officer for Gimoti™. In June 2020, Gimoti was approved by the Food and Drug Administration for the relief of symptoms in
-
Evoke Pharma Reports Second Quarter 2020 Financial ResultsPreparing for commercial launch of GIMOTI™ in 4Q 2020
8/6/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2020. “The recent FDA approval of Gimoti, the first and only outpatient treatment option that bypasses the stomach to relieve symptoms in adults with acute and recurrent diabetic gastroparesis, marked the most significant milestone in o
-
Evoke Pharma Initiates Commercial Manufacturing of Gimoti™Preparing commercial launch of GIMOTI™ in 4Q 2020
7/15/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has initiated the commercial manufacturing of Gimoti™ (metoclopramide) nasal spray with its manufacturing partner, Patheon, a division of Thermo Fisher Scientific, Inc. Gimoti was approved by the U.S. Food and Drug Administration on June 19, 2020 for the relief of symptoms in adults with a
-
Evoke Pharma Extends Cash Runway to 2Q 2021Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020
7/8/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that as of June 30, 2020 it had cash and cash equivalents of approximately $8.0 million. Based on its current operating plan, Evoke believes that its existing cash and cash equivalents will provide sufficient cash to fund its operations into the second quarter of 2021, without consideration of th
-
FDA Approves Evoke’s GIMOTI™
6/19/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for GIMOTI™
-
The next two weeks are busy ones for the U.S. Food and Drug Administration (FDA). Here’s a look at PDUFA dates for this period.
-
Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission
5/20/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary brand name, “Gimoti,” for the Company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis as resubmitted in the 505(b)(2) New Drug Applic
-
Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format
5/12/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2020, and that it will hold its 2020 annual meeting of stockholders virtually by means of remote communication to help protect the health and safety of employees and s
-
Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial ResultsGimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020
3/12/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2019.
-
Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™
1/27/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the Gimoti™ trademark.
-
Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™
1/23/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, an independent provider of global commercial services to the life science industry, today announced a collaboration to utilize EVERSANA’s integrated suite of outsourced services to commercialize and distribute Gimoti™ in the United States (U.S.).
-
FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™PDUFA Target Goal Date is June 19, 2020
1/21/2020
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s resubmission of its 505(b)(2) New Drug Application (NDA) for Gimoti™
-
Evoke Resubmits Gimoti™ New Drug Application to FDA
12/20/2019
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Gimoti™,
-
Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement
12/2/2019
Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that on November 29, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement under Nasdaq’s Marketplace Rule 5550 for continued listing on the Nasdaq Capital Market.
-
Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price
11/13/2019
Evoke Pharma, Inc. (NASDAQ: EVOK), today announced that on November 12, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has been granted an additional 180-day grace period to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq’s Marketplace Rule 5550(a)(2).
-
BioSpace Movers & Shakers, Nov. 8
11/8/2019
Pharmaceutical, medtech and biotech companies expand their leadership teams with this week's appointments. -
Karsten Risch joins Evoke as Chief Medical Officer
11/7/2019
Risch brings more than 30 years of experience in medical strategy leadership to clients across the globe.
-
Evoke Pharma Reports Third Quarter 2019 Financial ResultsGimoti NDA resubmission on track for fourth quarter 2019
11/7/2019
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2019.
-
The CRL is not totally unexpected, given that last month the company received a multi-disciplinary review (DR) letter from the FDA regarding its New Drug Application.